8 April 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
28 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary results LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its maiden audited preliminary results for the year ended 31 December 2021, following admission to trading on AIM on 8 July 2021. Summary and Highlights for the year: Revenues […]
LungLife AI licensure/accreditation information posted here.